Dyne Therapeutics Inc (NASDAQ:DYN) shares, rose in value on Wednesday, July 09, with the stock price up by 5.84% to the previous day’s close as strong demand from buyers drove the stock to $8.88.
Actively observing the price movement in the last trading, the stock closed the session at $8.39, falling within a range of $8.46 and $9.3. The value of beta (5-year monthly) was 1.163. Referring to stock’s 52-week performance, its high was $47.45, and the low was $6.36. On the whole, DYN has fluctuated by -39.59% over the past month.
With the market capitalization of Dyne Therapeutics Inc currently standing at about $1.26 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-08.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that DYN’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of DYN currently trading nearly -17.85% and -23.21% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.33, while the 7-day volatility ratio is showing 6.96% which for the 30-day chart, stands at 7.41%. Furthermore, Dyne Therapeutics Inc (DYN)’s beta value is 1.09.
A comparison of Dyne Therapeutics Inc (DYN) with its peers suggests the former has fared considerably weaker in the market. DYN showed an intraday change of 5.84% in last session, and over the past year, it shrunk by -62.31%%.
Data on historical trading for Dyne Therapeutics Inc (NASDAQ:DYN) indicates that the trading volumes over the past 10 days have averaged 4.0 and over the past 3 months, they’ve averaged 2.86 million. According to company’s latest data on outstanding shares, there are 113.63 million shares outstanding.
Nearly 25.01% of Dyne Therapeutics Inc’s shares belong to company insiders and institutional investors own 67.33% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 20.62 million shares as on 2025-06-13, resulting in a short ratio of 10.91. According to the data, the short interest in Dyne Therapeutics Inc (DYN) stood at 2086.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 23.2 million. The stock has fallen by -74.19% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the DYN stock heading into the next quarter.
